Atrimustine
Atrimustine ( developmental code name KM-2210; former tentative brand name Kregan ) , also known as bestrabucil or busramustine , is a cytostatic antineoplastic agent which was under development in Japan by Kureha Chemicals ( now Kureha Corporation ) for the treatment of breast cancer and non-Hodgkin's lymphoma as well as for the prevention of graft-versus-host disease in bone marrow transplant recipients . 
<triplet> Kureha Chemicals <subj> Japan <obj> country